Trump Administration Withdraws Key ADA Documents

The Trump administration has removed 11 guidance documents that helped businesses follow the Americans with Disabilities Act (ADA), a new report says.

The documents were withdrawn last month as part of a federal effort to reduce rules that businesses must follow. 

The Department of Justice (DOJ) said the goal was to cut costs an...

Key HIV Care Teams Let Go, Putting Mothers and Children at Risk

The Trump administration has let go of the last remaining U.S. health officials who oversaw HIV care for more than 1.1 million mothers and children in low-income countries.

The move raises alarms about how these vulnerable groups will get care.

The officials — who worked in multiple U.S. agencies, including the Centers for Dise...

'Zero Suicide' Model Leads To Fewer Suicides in Health Systems

A health care program focused on suicide prevention has helped lower suicides and attempts, a new study shows.

The program, called the "Zero Suicide Model," relies on screening, safety planning and mental health support to help people at risk, The Associated Press reported.

The program included collaborating with patients to...

Stroke, Dementia, Depression Share Many Risk Factors

Brain diseases like stroke, dementia and depression share common risk factors, and changing any can lower a person’s risk of all three conditions, a new study says.

Addressing factors as varied as blood pressure, blood sugar, cholesterol, physical activity, sleep, stress, alcohol consumption and smoking can significantly reduce risk ...

Diet Drinks, Processed Foods Might Increase Type 2 Diabetes Risk

Food additive mixtures commonly found in diet drinks, soups, dairy desserts and sauces may slightly increase a person’s risk of type 2 diabetes, a new study says.

A mixture of additives commonly found in artificially sweetened beverages increased risk of type 2 diabetes by 13% among a group of nearly 110,000 people, researchers repor...

Experimental Drug Can Slow MS Disability

An experimental drug can help patients with advanced multiple sclerosis (MS) delay the progressive disability that comes with their disorder, a new clinical trial suggests.

The drug, tolebrutinib, delayed disability progression by 31% in people with a type of MS called non-relapsing secondary progressive multiple sclerosis (SPMS), research...